-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Equal-Weight on RxSight, Lowers Price Target to $6

Benzinga·11/04/2026 15:41:22
Diffusion vocale
Wells Fargo analyst Larry Biegelsen maintains RxSight (NASDAQ:RXST) with a Equal-Weight and lowers the price target from $9 to $6.